Skip to content
10-K

Annual Report

Kyverna Therapeutics, Inc. KYTX

0001193125-26-126242

← back to feed
Filed
Mar 26, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 1, 2026 60.44M sh
Shares Diluted FY 2025 · Dec 31, 2025 44.26M sh
Shares Diluted FY 2025 · Dec 31, 2024 38.33M sh
Capex FY 2025 · Dec 31, 2025 $5K
Capex FY 2025 · Dec 31, 2024 $2.21M
Operating Cash Flow FY 2025 · Dec 31, 2025 −$153.71M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$114.25M
Cash And Equivalents FY 2025 · Dec 31, 2025 $124.09M
Cash And Equivalents FY 2025 · Dec 31, 2024 $96.62M
Stockholders Equity FY 2025 · Dec 31, 2025 $232.28M
Stockholders Equity FY 2025 · Dec 31, 2024 $266.59M
Stockholders Equity restated FY 2025 · Dec 31, 2023 −$13.14M
Current Liabilities FY 2025 · Dec 31, 2025 $36.49M
Current Liabilities FY 2025 · Dec 31, 2024 $33.76M
Total Liabilities FY 2025 · Dec 31, 2025 $61.55M
Total Liabilities FY 2025 · Dec 31, 2024 $38.06M
Current Assets FY 2025 · Dec 31, 2025 $282.95M
Current Assets FY 2025 · Dec 31, 2024 $290.6M
Total Assets FY 2025 · Dec 31, 2025 $293.83M
Total Assets FY 2025 · Dec 31, 2024 $304.65M
Eps Diluted FY 2025 · Dec 31, 2025 −$3.64
Eps Diluted FY 2025 · Dec 31, 2024 −$3.33
Eps Basic FY 2025 · Dec 31, 2025 −$3.64
Eps Basic FY 2025 · Dec 31, 2024 −$3.33
Sga Expense FY 2025 · Dec 31, 2025 $36.11M
Sga Expense FY 2025 · Dec 31, 2024 $30.13M
Rd Expense FY 2025 · Dec 31, 2025 $133.72M
Rd Expense FY 2025 · Dec 31, 2024 $112.47M
Net Income FY 2025 · Dec 31, 2025 −$161.31M
Net Income FY 2025 · Dec 31, 2024 −$127.48M
Operating Income FY 2025 · Dec 31, 2025 −$169.83M
Operating Income FY 2025 · Dec 31, 2024 −$142.6M